ETON - Eton Pharmaceuticals, Inc.
7.36 0.00 (0.00%)
After hours: 4:00PM EDT
| Previous Close | 7.35 |
| Open | 7.44 |
| Bid | 7.36 x 1300 |
| Ask | 7.39 x 800 |
| Day's Range | 7.12 - 7.97 |
| 52 Week Range | 5.70 - 10.20 |
| Volume | 8,613 |
| Avg. Volume | 40,712 |
| Market Cap | 129.741M |
| Beta (3Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -4.13 |
| Earnings Date | Aug 7, 2019 - Aug 13, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- American City Business Journals•9 hours ago
The city's newest public company wants to build a new industry in Nashville
“If we can bring the right people and the right brains and build out the infrastructure, we think we can build the industry,” Harrow Health CEO Mark Baum said.
- American City Business Journals•yesterday
Publicly traded San Diego firm moving HQ to Nashville
A publicly traded health care company is relocating from the West Coast to Nashville — but it won’t be the typical Middle Tennessee health care firm.
- Benzinga•5 days ago
The Daily Biotech Pulse: Hematology And Rheumatology Conference Presentations Take The Spotlight, Eton In-Licenses Epilepsy Drug NDA
The following is a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs June 12) • Abbott Laboratories (NYSE: ABT ) • Avedro ...
- GlobeNewswire•6 days ago
Eton Pharmaceuticals Announces Licensing of Lamotrigine New Drug Application and Provides Pipeline Update
Eton Pharmaceuticals, Inc (ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug products, today announced that the Company has entered into an agreement with Aucta Pharmaceuticals, Inc to acquire U.S. marketing rights for ET-105. Aucta submitted the product’s New Drug Application (NDA) to the FDA in May 2019 and is seeking approval as an epilepsy treatment to be used as an adjunct therapy for partial seizures, primary generalized tonic-clonic seizures, and generalized seizures of Lennox-Gastaut syndrome in patients two years of age and older.
- Simply Wall St.•27 days ago
How Many Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Shares Did Insiders Buy, In The Last Year?
We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. The...
- GlobeNewswire•last month
Eton Pharmaceuticals to Present at 20th Annual B. Riley FBR Investor Conference
DEER PARK, Ill., May 15, 2019 -- Eton Pharmaceuticals, Inc. (NASDAQ: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug.
- GlobeNewswire•last month
Eton Pharmaceuticals Reports First Quarter 2019 Financial Results and Highlights Business Progress
– Four Products Currently Under Review with the FDA – – Expecting Multiple Product Launches in Second Half of 2019 – – Company to Host Conference Call and Webcast today at.
- Zacks•last month
Bausch's (BHC) Q1 Earnings Beat Estimates, Revenues Miss
Bausch (BHC) Q1 earnings surpass estimates, while revenues miss the same. The increase in guidance was impressive.
- GlobeNewswire•2 months ago
Eton Pharmaceuticals to Report First Quarter 2019 Financial Results on Tuesday, May 7, 2019
DEER PARK, Ill., April 30, 2019 -- Eton Pharmaceuticals, Inc. (NASDAQ: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug.
- GlobeNewswire•3 months ago
Eton Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results and Highlights Business Progress
DEER PARK, Ill., March 25, 2019 -- Eton Pharmaceuticals, Inc. (NASDAQ: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug.
- GlobeNewswire•3 months ago
Eton Pharmaceuticals Submits New Drug Application for DS-200
Eton Pharmaceuticals, Inc. (ETON), today announced that the Company has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for DS-200 via the Rolling Review process. DS-200 was previously granted Fast Track Designation by the FDA. “The commencement of the NDA submission process for DS-200 marks an important milestone for Eton as we continue to progress DS-200 and our broader late stage pipeline with a new total of four products applications submitted to the FDA,” said Sean Brynjelsen, Chief Executive Officer of Eton Pharmaceuticals.
- Zacks•4 months ago
Bausch (BHC) Q4 Earnings Beat Estimates, Revenues Down Y/Y
Bausch (BHC) Q4 earnings and revenues surpass estimates. However, guidance for 2019 is not impressive.
- GlobeNewswire•4 months ago
Eton Pharmaceuticals to Present at the 8th Annual SVB Leerink Healthcare Conference
DEER PARK, Ill., Feb. 21, 2019 -- Eton Pharmaceuticals, Inc. (NASDAQ: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug.
- Benzinga•4 months ago
The Daily Biotech Pulse: Teva Settles With FTC, Setback For Merck In Liver Cancer Trial, Sienna Biopharma Offering
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks hitting 52-week highs on Feb. 19) Alector Inc (NASDAQ: ALEC ) (IPOed early February) ...
- PR Newswire•4 months ago
Bausch Health Acquires Eton Pharmaceuticals' EM-100 Investigational Eye Drop For The Treatment Of Itchy Eyes Associated With Allergies
If Approved, EM-100 Will Be the First OTC Preservative-Free Formulation of Its Kind EM-100 Has Been Submitted to the FDA for Review LAVAL, Quebec and DEER PARK, Ill. , Feb. 19, 2019 /PRNewswire/ -- Bausch ...
- GlobeNewswire•4 months ago
Eton Pharmaceuticals Enters Into License Agreement for Two Branded Hospital Product Candidates
Eton Pharmaceuticals, Inc. (ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug products, today announced that it has entered into an exclusive licensing and supply agreement with Sintetica SA, a Swiss-based pharmaceutical company, to obtain U.S. marketing rights to two injectable product candidates. With the addition of these product candidates, Eton now has three product candidates submitted with the FDA and expects to submit two additional NDAs by the third quarter of 2019.
- Benzinga•5 months ago
The Daily Biotech Pulse: Intuitive Surgical Earnings, Corbus To Offer Shares, Eton In-Licenses Neurologic Drug
Here's a roundup of top developments in the biotech space over the last 24 hours. No biotech stocks hit 52-week peaks Thursday. Down In The Dumps (Biotech stocks hitting 52-week lows on Jan. 24) Amneal ...
- GlobeNewswire•5 months ago
Eton Pharmaceuticals Announces Licensing of Oral Liquid Product Candidate ET-104
ET-104’s active ingredient is approved and marketed in an oral solid formulation, but the active ingredient is not approved by the U.S. Food and Drug Administration (FDA) in liquid form. Presently, patients requiring liquid formulations of the active ingredient are reliant on compounded products.
- GlobeNewswire•6 months ago
Eton Pharmaceuticals Reports Third Quarter Results and Business Update
Licensed High-Value Injectable Product Candidate Successfully Completed Initial Public Offering DEER PARK, Ill., Dec. 20, 2018 -- Eton Pharmaceuticals, Inc. (NASDAQ: ETON), a.
- GlobeNewswire•7 months ago
Imprimis Pharmaceuticals Ranked 88th Fastest Growing Company in North America on Deloitte’s 2018 Technology Fast 500™
Imprimis Pharmaceuticals, Inc. (IMMY) today announced that it ranked 88th on Deloitte’s Technology Fast 500™, a ranking of the 500 fastest growing technology, media, telecommunications, life sciences and energy tech companies in North America. Winners were selected based on percentage fiscal year revenue growth from 2014 to 2017, and Imprimis grew 1,513% during this period. “Congratulations to the Deloitte 2018 Technology Fast 500 winners on this impressive achievement,” said Sandra Shirai, vice chairman, Deloitte LLP, and U.S. technology, media and telecommunications leader.
- GlobeNewswire•7 months ago
Eton Pharmaceuticals Announces Pricing of Initial Public Offering
Eton Pharmaceuticals, Inc (ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug products, today announced the pricing of its initial public offering of 3,600,000 shares of its common stock at a public offering price of $6.00 per share. All of the shares are being offered by Eton. In addition, Eton has granted the underwriter a 45-day option to purchase an additional 540,000 shares of common stock at the initial public offering price, less underwriting discounts and commissions.
- Benzinga•8 months ago
IPO Outlook For The Week: Banks And Biotechs
For a more comprehensive IPO calendar, check out the offering in Benzinga Cloud . IPO dates are expected, not confirmed, at time of publication. BankFlorida (BFL) will issue 6.2 million shares between ...
